What are the rules on importing and possessing peptides and GLP-1s in Portugal and Spain?

The short answer

Portugal has the harshest possession provision we have found anywhere in Europe, and almost nobody writing about peptides mentions it. Article 57 of Lei n.º 81/2021 punishes anyone who buys, imports, transports or unlawfully holds a substance on the prohibited list with one to five years' imprisonment — with no quantity threshold of any kind. The offence is defined solely by the substance being listed.

Germany sets milligram thresholds. Denmark and Norway criminalise possession but cap the penalty at two years and six months respectively. Portugal sets no threshold and goes to five.

And the Portuguese medicines regulator does not authorise personal importation at all — not from outside the EU, and not, on the face of its guidance, from inside it either.

Evidence tier: Tier 1 for Portuguese statutes and regulator circulars, read directly. Spain is covered more thinly and we say where. Educational content, not medical or legal advice.

The key points:

• Portugal: 1–5 years for holding a listed substance, no threshold, anyone.
• INFARMED does not authorise personal import. Intercepted parcels are destroyed, analysed or returned.
• BPC-157 is expressly on the list Portugal's criminal provision refers to — unlike Germany's.
• GLP-1s are not prohibited, only monitored — a critical distinction.
• Obesity reimbursement: none as at early 2026, at roughly €250–300 a month.

Portugal does not permit personal importation

Evidence tier: 1 — INFARMED circular read directly.

INFARMED's position is unusually blunt. From Circular Informativa n.º 148/CD of 29 July 2011:

"esta importação não tem suporte legal e acarreta riscos para a saúde dos consumidores… Assim, o Infarmed não autoriza a importação de medicamentos para uso pessoal."

Private importation has no legal basis, and the agency does not authorise it. The circular is equally direct about consequences: imported medicines "não são desalfandegados, mas sim destruídos, analisados ou devolvidos à procedência, pelo que os consumidores perdem o montante dispendido" — not cleared through customs but destroyed, analysed or returned, and the buyer loses the money.

Consumers may acquire medicines only at pharmacies and licensed non-prescription retail points. The postal operator suspends suspect consignments pending INFARMED's decision.

One warning we want to be explicit about, because it is the most likely error a reader will make. Germany permits postal import from inside the EU/EEA under a specific statutory exception. Portugal has no equivalent provision that we could find, and Circular 148/2011 is written in general terms rather than being limited to third countries. Do not assume symmetry. On the available evidence Portugal is materially stricter, and we are not going to assert that intra-EU personal import is lawful there.

There is also no Portuguese equivalent of the German three-month allowance. We found no instrument fixing a quantity ceiling for ordinary prescription medicines. The one numeric limit in the circular concerns controlled substances: a traveller may carry 30 days' treatment for personal use with medical justification.

The possession offence has no threshold

Evidence tier: 1 — consolidated statute read directly.

First, a correction that matters for anyone researching this. Lei n.º 38/2012 has been repealed. The governing instrument is Lei n.º 81/2021 of 30 November, as amended by Decreto-Lei n.º 35/2022. Commentary still citing the 2012 law is out of date.

Article 57 reads, in relevant part:

"Quem, sem que para tal se encontre autorizado, produzir, fabricar, extrair, preparar, oferecer, puser à venda, vender, distribuir, comprar, ceder, ou por qualquer título receber, proporcionar a outrem, transportar, importar, exportar ou fizer transitar ou ilicitamente detiver substâncias e métodos constantes da lista de substâncias e métodos proibidos é punido com pena de prisão de 1 a 5 anos."

"Quem" is a general criminal norm — anyone. Buying, importing, transporting or unlawfully holding a listed substance carries one to five years, rising by a third where the person acts with intent to breach anti-doping rules.

There is no quantity threshold. The offence turns entirely on whether the substance appears on the prohibited list.

A separate and much softer regime exists for athletes: Article 62 creates an administrative offence of possession in or out of competition by a sportsperson or someone connected to them, punishable by a fine of 35 to 98 units of account, investigated by ADoP with appeal to the sports arbitration tribunal. That is the provision most people find first. It is not the one that reaches a private individual.

What is actually on the list

Evidence tier: 1 — WADA 2026 list as adopted nationally.

Portugal applies the WADA prohibited list, with the 2026 edition in force from 1 January 2026. Section S2.2.4 covers the peptide classes in full:

• GHRH and analogues — CJC-1293, CJC-1295, sermorelin, tesamorelin
• GH secretagogues and mimetics — anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin, tabimorelin
• GHRPs — alexamorelin, examorelin (hexarelin), GHRP-1 through GHRP-6

Section S2.2.3 covers growth hormone, its analogues and fragments including AOD-9604 and hGH 176-191. Section S2.3 covers IGF-1, mechano growth factors and thymosin-beta-4 and derivatives, naming TB-500. All S2 substances are prohibited at all times, in and out of competition, and are non-Specified.

Section S0 expressly names BPC-157. This is the sharpest contrast with Germany in the whole series: BPC-157 is absent from the German annex, so it sits outside German criminal doping law — but it is squarely on the list that Portugal's threshold-free, five-year Article 57 refers to.

GLP-1 drugs are not prohibited. Semaglutide and tirzepatide were added to WADA's Monitoring Program for 2026, and monitored substances are not prohibited substances under Article 4.5 of the Code. This distinction is easy to misread and worth stating plainly: being monitored is not being banned.

Reimbursement and supply

Evidence tier: 1 for the circular quotation; 2 for current status.

Type-2 diabetes only. INFARMED's July 2024 circular states the medicines are reimbursed "apenas… para o tratamento da diabetes tipo 2, como adjuvante à dieta e exercício… para ser utilizado em segunda e terceira linhas terapêuticas" — second and third line, not first.

No obesity reimbursement as at early 2026, with patients reported to be paying roughly €250–300 a month. Despacho n.º 13066/2025 of 6 November created a national obesity programme and tasked INFARMED with an impact study on reimbursing obesity medicines. Whether any decision followed between February and September 2026 is unverified, and this is the item on the page most likely to have moved. Check before relying on it.

On shortages, the same 2024 circular is candid about cause: the shortage of Ozempic, Trulicity and Victoza was expected to persist through 2024 and 2025, and "A utilização destes medicamentos para indicações que não se encontram aprovadas, nomeadamente na perda de peso, tem contribuído, de forma significativa para o agravamento da situação." Pharmacies were instructed to check prescription and dispensing history before dispensing, to prevent hoarding.

Enforcement is aimed at parcels, and the buyers behind them

Evidence tier: 1 for the INFARMED alert; 2 for customs figures.

INFARMED issued an alert on 5 September 2025 on a sharp rise in illegal medicines marketed as GLP-1 analogues — semaglutide, liraglutide and tirzepatide — sold through fraudulent sites and promoted on social media. Authorities identified hundreds of fake social media profiles, and the response described includes product withdrawal, site blocking and cross-border cooperation.

Portuguese customs reported 276,326 counterfeit medicine units seized in 2025 across 1,740 postal consignments — an average of 757 a day — down 28% on 2024, with rising seizures of falsified weight-loss medicines. The characterisation matters: "a maioria destes medicamentos resulta de compras efetuadas por particulares através da internet" — most result from purchases by private individuals over the internet. India was the largest origin at 65.2%.

On online purchase, Portugal is categorical. Prescription medicines may only be sold in pharmacies, and online acquisition is possible only through the websites of licensed pharmacies and registered non-prescription retailers. Legitimate sellers display the EU common logo linking to the national register; its absence indicates a fraudulent site.

Spain: verified framework, unverified detail

Evidence tier: 2 — statutory framework only.

We are giving Spain less space than Portugal, and the reason is verification rather than importance.

Spain's statutory framework is confirmed — AEMPS is the medicines agency, and the general structure of medicines and anti-doping regulation is established. But the AEMPS pages we needed for the operational detail — supply problems, safety notices, informational notes — are JavaScript applications that returned nothing to us, and we did not obtain the personal-import quantity rules or a current enforcement record.

One correction from our own earlier research, since it circulates in secondary sources: Ley Orgánica 11/2021 is dated 28 December, not 28 May.

Rather than pad this section to match Portugal's length, we are marking it as incomplete. A Spanish reader should not treat the absence of detail here as evidence that Spain is permissive — we simply could not read the sources.

What we could not verify

• Whether Portugal distinguishes intra-EU from third-country personal import. We found no such distinction and will not assert one in either direction.
• Whether obesity reimbursement changed after INFARMED's impact study. The study PDF exceeded our fetcher's limits.
• Marketing status in Portugal for Wegovy, Saxenda, Rybelsus and Mounjaro. All hold EU authorisations; the national database is a JavaScript extranet.
• The current value of the Portuguese unit of account, so no euro figure is given for the athlete fines.
• The specific Portuguese instrument restricting distance selling to non-prescription medicines. The EU basis is Article 85c of Directive 2001/83/EC; we did not confirm the national article.
• Portaria n.º 431/2025/1, the presumed instrument adopting the 2026 prohibited list.
• Spain: personal-import quantities, agency notices, and enforcement record.
• Whether any Portuguese enforcement action has specifically targeted peptide vendors. We found none.

Limitations

This is educational content. It is not legal advice, and it is not medical advice.

• Portugal's Article 57 has no quantity threshold. Do not reason from German or Nordic thresholds.
• Lei n.º 38/2012 is repealed. Sources citing it are out of date.
• We describe what the law says, not what to do. Nothing here is guidance on obtaining unapproved medicines, and we name no vendors or routes.
• The Portuguese medicines statute is on its 19th version, most recently amended in June 2026. Re-check anything quoted.
• Spain is deliberately incomplete. Absence of detail is not evidence of permissiveness.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Portugal is the outlier of this series, and in the opposite direction from its reputation. It sets no quantity threshold at all for criminal possession of a listed substance, reaches anyone rather than only athletes, and carries up to five years — a longer maximum than Germany, Denmark or Norway. Its medicines regulator states in writing that it does not authorise personal importation, and that intercepted parcels are destroyed or returned with the buyer simply losing the money.

The BPC-157 divergence is worth carrying between the two guides. In Germany it is absent from the criminal annex. In Portugal it is expressly named in S0 of the list that Article 57 points at. Same compound, same continent, entirely different criminal exposure — which is the clearest possible illustration of why "is it legal in Europe" is not a question with an answer.

And the distinction that saves most readers: GLP-1s are monitored, not prohibited. They sit outside the doping provisions entirely, and their legal profile is medicines and customs law. It is the growth-hormone peptides that engage both.

Related on this site

• Peptides in Germany, Austria and Switzerland
• Peptides in the Nordics: import rules and doping law
• Peptides in the Baltics
• Peptides in Benelux
• Peptides in Central & Eastern Europe
• BPC-157: animal vs human evidence reviewed
• Are peptides legal in the European Union?

References

• Portugal, personal import: INFARMED Circular Informativa n.º 148/CD of 29 July 2011, Importação de medicamentos para uso pessoal. Circular PDF · Ministry of Health mirror
• Portugal, postal procedure: CTT guidance on suspected prohibited imports of medicines
• Portugal, anti-doping: Lei n.º 81/2021 of 30 November, as amended by DL n.º 35/2022, arts. 57.º, 58.º, 59.º, 62.º, 63.º. Consolidated text — repeals Lei n.º 38/2012.
• Prohibited list: WADA 2026 list, in force 1 January 2026, as adopted nationally. ADoP announcement · List PDF — S2.2.3, S2.2.4, S2.3; S0 names BPC-157; semaglutide and tirzepatide on the Monitoring Program.
• Portugal, medicines statute: Decreto-Lei n.º 176/2006, art. 14.º n.º 1 and arts. 176.º, 181.º, 181.º-A. INFARMED consolidated PDF · pgdlisboa consolidated
• Portugal, illegal GLP-1 alert: INFARMED, 5 September 2025, on EMA/HMA warning over illegal GLP-1 analogues. Alert
• Portugal, reimbursement and shortages: INFARMED circular, July 2024, quoted verbatim in Lusa reporting
• Portugal, customs seizures 2025: Grupo Anti Contrafação report — 276,326 units across 1,740 postal consignments. Reporting